An Improved MobileNet for Disease Detection on Tomato Leaves

Tomatoes are widely grown vegetables, and farmers face challenges in caring for them, particularly regarding plant diseases. The MobileNet architecture is renowned for its simplicity and compatibility with mobile devices. This study introduces MobileNet as a deep learning model to enhance disease detection efficiency in tomato plants. The model is evaluated on a dataset of 2,064 tomato leaf images, encompassing early blight, leaf spot, yellow curl, and healthy leaves. Results demonstrate promising accuracy, exceeding 0.980 for disease classification and 0.975 for distinguishing between diseases and healthy cases. Moreover, the proposed model outperforms existing approaches in terms of accuracy and training time for plant leaf disease detection

VinDr-CXR: An open dataset of chest X-rays with radiologist’s annotations

Measurement(s) diseases and abnormal findings from chest X-ray scans Technology Type(s) AI is used to detect diseases and abnormal findings Sample Characteristic - Location Vietna

Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization

Despite their promise, circulating tumor DNA (ctDNA)-based assays for multi-cancer early detection face challenges in test performance, due mostly to the limited abundance of ctDNA and its inherent variability. To address these challenges, published assays to date demanded a very high-depth sequencing, resulting in an elevated price of test. Herein, we developed a multimodal assay called SPOT-MAS (screening for the presence of tumor by methylation and size) to simultaneously profile methylomics, fragmentomics, copy number, and end motifs in a single workflow using targeted and shallow genome-wide sequencing (~0.55×) of cell-free DNA. We applied SPOT-MAS to 738 non-metastatic patients with breast, colorectal, gastric, lung, and liver cancer, and 1550 healthy controls. We then employed machine learning to extract multiple cancer and tissue-specific signatures for detecting and locating cancer. SPOT-MAS successfully detected the five cancer types with a sensitivity of 72.4% at 97.0% specificity. The sensitivities for detecting early-stage cancers were 73.9% and 62.3% for stages I and II, respectively, increasing to 88.3% for non-metastatic stage IIIA. For tumor-of-origin, our assay achieved an accuracy of 0.7. Our study demonstrates comparable performance to other ctDNA-based assays while requiring significantly lower sequencing depth, making it economically feasible for population-wide screening